Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Eptifibatide Injection in both 20 mg per 10 mL SDV and 75 mg per 100 mL SDV.
· 71288-412-10: Eptifibatide Injection 20 mg per 10 mL SDV
· 71288-413-51: Eptifibatide Injection 75 mg per 100 mL SDV
ABOUT EPTIFIBATIDE INJECTION
Eptifibatide Injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with Acute Coronary Syndrome (ACS), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). Eptifibatide Injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.
For full prescribing information, please click on the following link.
Learn more about Eptifibatide Injection.
